Xiangxue Pharmaceutical Asset Resilience Ratio
Xiangxue Pharmaceutical asset resilience ratio. Xiangxue Pharmaceutical (300147) has an Asset Resilience Ratio of 0.05% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Xiangxue Pharmaceutical to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Xiangxue Pharmaceutical (2010–2024)
Asset resilience ratio of Xiangxue Pharmaceutical from 2010 to 2024. This chart shows how Xiangxue Pharmaceutical's Asset Resilience Ratio has changed over time. Read Xiangxue Pharmaceutical debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Xiangxue Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Xiangxue Pharmaceutical assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥4.00 Million | 0.05% |
| Total Liquid Assets | CN¥4.00 Million | 0.05% |
Asset Resilience Insights
- Limited Liquidity: Xiangxue Pharmaceutical maintains only 0.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Xiangxue Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Xiangxue Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Xiangxue Pharmaceutical Asset Resilience Ratio by Year (2010–2024)
Xiangxue Pharmaceutical asset resilience ratio by year from 2010 to 2024. The table below shows the annual Asset Resilience Ratio data for Xiangxue Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.17% | CN¥13.00 Million ≈ $1.90 Million |
CN¥7.50 Billion ≈ $1.10 Billion |
+0.67pp |
| 2023-12-31 | -0.49% | CN¥-40.87 Million ≈ $-5.98 Million |
CN¥8.28 Billion ≈ $1.21 Billion |
-0.49pp |
| 2022-12-31 | 0.00% | CN¥125.98K ≈ $18.43K |
CN¥9.35 Billion ≈ $1.37 Billion |
-0.58pp |
| 2021-12-31 | 0.58% | CN¥65.63 Million ≈ $9.60 Million |
CN¥11.38 Billion ≈ $1.67 Billion |
+0.38pp |
| 2020-12-31 | 0.20% | CN¥19.34 Million ≈ $2.83 Million |
CN¥9.78 Billion ≈ $1.43 Billion |
-0.14pp |
| 2019-12-31 | 0.34% | CN¥28.54 Million ≈ $4.18 Million |
CN¥8.46 Billion ≈ $1.24 Billion |
+0.07pp |
| 2018-12-31 | 0.27% | CN¥23.34 Million ≈ $3.41 Million |
CN¥8.63 Billion ≈ $1.26 Billion |
+0.44pp |
| 2017-12-31 | -0.17% | CN¥-16.17 Million ≈ $-2.37 Million |
CN¥9.44 Billion ≈ $1.38 Billion |
-0.50pp |
| 2016-12-31 | 0.33% | CN¥26.36 Million ≈ $3.86 Million |
CN¥7.99 Billion ≈ $1.17 Billion |
-0.13pp |
| 2015-12-31 | 0.46% | CN¥21.27 Million ≈ $3.11 Million |
CN¥4.65 Billion ≈ $680.73 Million |
+0.64pp |
| 2014-12-31 | -0.18% | CN¥-6.46 Million ≈ $-944.87K |
CN¥3.59 Billion ≈ $525.08 Million |
-0.19pp |
| 2010-12-31 | 0.01% | CN¥203.67K ≈ $29.80K |
CN¥1.85 Billion ≈ $270.22 Million |
-- |
About Xiangxue Pharmaceutical
Xiangxue Pharmaceutical Co.,Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, diet sa… Read more